Neumora Therapeutics, Inc. (NMRA) AI Stock Analysis

• Market Cap: $139.69M
• Dividend Yield: N/A
• Average Volume (3M): 880.81K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.21
• Revenue Growth: N/A
• EPS Growth: -0.42%
• Country: US
• Employees: 110
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -0.42
• Shares Outstanding: 161,747,920
• 10 Day Avg. Volume: 1,054,832
• 30 Day Avg. Volume: 880,810
• PEG Ratio: -2.58
• Price to Book (P/B): 5.89
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.23
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $6.40
• Price Target Upside: 710.13% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 33 Underperform
• Price Target: ―

Neumora Therapeutics, Inc. is significantly challenged by its financial position, with ongoing losses and no revenue. Technical analysis indicates bearish momentum, and valuation is difficult in the absence of earnings. While promising pipeline advancements and a strong cash position offer some optimism, the overall outlook is hindered by recent clinical setbacks and financial instability.

Positive Factors

Financial Performance

The announcement of a non-dilutive debt financing with K2 HealthVentures extends the cash runway into 2027 and potentially beyond, providing a strong financial position.

Innovation and Pipeline

Neumora's focus on innovative pipeline assets like the V1aR antagonist and M4 programs offers potential for meaningful shareholder value.

Operational Improvements

Operational changes have enhanced medical monitoring and partnerships, improving the probability of success for KOASTAL-2 and -3 studies.

Negative Factors

Clinical Challenges

The failure of the KOASTAL-1 study and J&J discontinuing aticaprant development continues to be an overhang on the stock.

Market Competition

The rest of the pipeline still requires clinical validation, raising concerns about being late to market compared to competitors.

Program Delays

Delayed timelines for the MDD program with the next update expected in 2026, impacting investor confidence.

Neumora Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

Neumora Therapeutics, Inc. generates revenue through the development and commercialization of its precision medicines. The company focuses on advancing its pipeline of investigational therapies through various stages of clinical trials, aiming for regulatory approval and subsequent market entry. Revenue is primarily derived from the successful commercialization of approved drugs. Additionally, Neumora may engage in strategic partnerships and collaborations with other pharmaceutical companies, which can include licensing agreements, joint ventures, or co-development arrangements, providing additional revenue streams and resources to support its research and development activities.

Neumora Therapeutics, Inc. Financial Statement Overview

Summary

Neumora Therapeutics, Inc. faces significant financial challenges with no revenue and substantial ongoing losses. While it maintains a strong cash position, financial instability is highlighted by negative equity and consistent cash outflows, indicating a dependency on external capital.

Income Statement

Neumora Therapeutics, Inc. has consistently reported zero revenue over the past several years, indicating a lack of monetization. All profitability metrics are negative, reflecting the company's inability to generate income. The company has significant ongoing losses, with a worsening EBIT and Net Income, suggesting high operational costs and financial strain typical for early-stage biotechnology firms.

Balance Sheet

The company maintains a strong cash position relative to its total assets, indicating good liquidity. However, continuing losses have resulted in negative equity in some years, posing a risk. The debt-to-equity ratio is not meaningful due to negative equity in prior periods, but low total debt suggests limited leverage. The equity position improved slightly, but overall financial health is weak.

Cash Flow

Neumora Therapeutics, Inc. shows consistent negative free cash flow, reflecting cash burn typical of R&D-heavy biotechnology companies. The cash flow from financing activities has been positive, indicating reliance on external funding to support operations. The operating cash flow has been negative, consistent with the lack of revenue generation.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-160.00K	0.00	-668.00K	-2.70M	-1.55M	0.00
	EBIT
-274.33M	-263.46M	-188.19M	-135.87M	-237.32M	-95.52M
	EBITDA
-273.85M	-242.98M	-187.53M	-135.28M	-236.78M	-95.41M
	Net Income Common Stockholders
-258.06M	-243.79M	-235.93M	-130.90M	-237.31M	-99.27M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
453.98M	307.58M	453.98M	371.88M	409.25M	191.98M
	Total Assets
496.19M	316.97M	496.19M	426.23M	429.30M	197.95M
	Total Debt
5.23M	1.85M	5.23M	8.44M	2.05M	2.04M
	Net Debt
-368.81M	-140.29M	-368.81M	-232.50M	-407.19M	-189.93M
	Total Liabilities
27.12M	29.91M	27.12M	873.08M	754.52M	292.33M
	Stockholders Equity
469.08M	287.06M	469.08M	-446.85M	-325.22M	-94.38M
Cash Flow		Free Cash Flow
-198.65M	-182.94M	-163.40M	-115.41M	-76.24M	-28.06M
	Operating Cash Flow
-199.43M	-182.94M	-163.28M	-114.90M	-75.42M	-26.76M
	Investing Cash Flow
123.60M	-70.56M	64.39M	-168.01M	-817.00K	-11.24M
	Financing Cash Flow
19.76M	21.60M	231.94M	115.74M	293.51M	230.10M

Neumora Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.79
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NMRA, the sentiment is Negative. The current price of 0.79 is below the 20-day moving average (MA) of 0.82, above the 50-day MA of 0.75, and below the 200-day MA of 5.81, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 46.54 is Neutral, neither overbought nor oversold. The STOCH value of 7.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NMRA.

Neumora Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EDIT	60 Neutral	$180.82M	―	-140.82%	―	-48.37%	-44.70%
Sector *	54 Neutral	$5.25B	3.27	-44.35%	6.27%	16.79%	-0.10%
CLLS	42 Neutral	$104.43M	―	-58.55%	―	825.97%	38.32%
NKTX	39 Underperform	$134.11M	―	-26.10%	―	―	30.76%
RAPT	39 Underperform	$1.09B	―	-75.60%	―	―	-2.29%
ALDX	37 Underperform	$180.88M	―	-65.19%	―	―	-47.28%
NMRA	33 Underperform	$139.69M	―	-79.05%	―	―	-0.42%

Neumora Therapeutics, Inc. Corporate Events

Neumora Therapeutics Announces Leadership Changes and Strategy

On February 13, 2025, Neumora Therapeutics announced leadership changes effective February 14, 2025, with Paul L. Berns transitioning to CEO and Chairman of the Board. Other key executives such as Joshua Pinto, Bill Aurora, and Michael Milligan have been assigned new roles. These changes are part of the company’s strategic efforts to enhance its position in the industry. Additionally, the Board approved an option repricing plan to incentivize key personnel, subject to stockholder approval, reflecting Neumora’s commitment to retaining talent while advancing its neuroscience initiatives.